IFNA2 and COVID-19: Our results indicated that convalescents had significantly higher levels of anti‐IFN‐alpha2 and anti‐IL‐15 IgG antibodies compared to the group with post‐COVID‐19 sequelae (Figure 3 A‐C; p < 0.001, Mann–Whitney U test; data in Supplement Table S1).